The company should have invested in a leader who has experience in negotiating deals, instead of an ex-FDA person who supposedly knows what it takes to get us across the line.
Don’t get me wrong, I have been a very patient investor who believes the science. Unfortunately, management has made way too many missteps.
As a LTH, that patience is finally wearing thin, and I think a great leader is one who recognises their blind spots and hires the right person and let’s them get on with the job of running the business so they can spend their time on the value proposition of our proprietary life saving portfolio…Mr SI
GLTAH, as sadly I may not be one for much longer….
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-340
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.015(1.04%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $3.815M | 2.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11031 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 14844 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |